Tscan therapeutics announces upcoming poster presentation at the 64th american society of hematology annual meeting and exposition

Waltham, mass., nov. 03, 2022 (globe newswire) --  tscan therapeutics, inc. (nasdaq: tcrx), a clinical-stage biopharmaceutical company focused on the development of t cell receptor (tcr)-engineered t cell therapies (tcr-t) for the treatment of patients with cancer, today announced the acceptance of a trial in progress abstract related to its lead candidates, tsc-100 and tsc-101, at the upcoming american society of hematology (ash) annual meeting and exposition, being held from december 10-13, 2022, in new orleans.
TCRX Ratings Summary
TCRX Quant Ranking